Cargando…

Total Neoadjuvant Therapy for Rectal Cancer in the CAO/ARO/AIO-12 Randomized Phase 2 Trial: Early Surrogate Endpoints Revisited

SIMPLE SUMMARY: Multimodal treatment of rectal cancer is undergoing dynamic change. In phase II/III multimodal rectal cancer trials, long-term survival remains the most objective endpoint for reporting treatment efficacy, but long follow-up is required, and there is a risk that the study results wil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Diefenhardt, Markus, Schlenska-Lange, Anke, Kuhnt, Thomas, Kirste, Simon, Piso, Pompiliu, Bechstein, Wolf O., Hildebrandt, Guido, Ghadimi, Michael, Hofheinz, Ralf-Dieter, Rödel, Claus, Fokas, Emmanouil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367426/ https://www.ncbi.nlm.nih.gov/pubmed/35954320 http://dx.doi.org/10.3390/cancers14153658

Ejemplares similares

Development and Validation of a Predictive Model for Toxicity of Neoadjuvant Chemoradiotherapy in Rectal Cancer in the CAO/ARO/AIO-04 Phase III Trial
por: Diefenhardt, Markus, et al.
Publicado: (2022)

ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group
por: Fleischmann, Maximilian, et al.
Publicado: (2022)

Acute toxicities of patients with locally advanced rectal cancer treated with intensified chemoradiotherapy within the CAO/ARO/AIO-12 trial: comparing conventional versus VMAT planning at a single center
por: Zimmermann, Marcus, et al.
Publicado: (2022)

Overall Survival After Treatment Failure Among Patients With Rectal Cancer
por: Diefenhardt, Markus, et al.
Publicado: (2023)

Eine Monotherapie mit Immuncheckpointblockade führt bei Patienten mit Rektumkarzinom und Mikrosatelliteninstabilität zur klinischen Komplettremission
por: Diefenhardt, Markus, et al.
Publicado: (2022)

Kurzzeitstrahlentherapie mit 5 × 5 Gy gefolgt von präoperativer Chemotherapie und Resektion bei Patienten mit lokal fortgeschrittenen Rektumkarzinomen führt zu einer Verbesserung des krankheitsfreien Überlebens
por: Kirste, Simon, et al.
Publicado: (2021)

RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV
por: Lorenzen, Sylvie, et al.
Publicado: (2020)

Surrogate endpoints.
por: Ellenberg, S. S.
Publicado: (1993)

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in combination with standard of care chemotherapy in primarily untreated chemo naïve upper gi-adenocarcinomas with peritoneal seeding – a phase II/III trial of the AIO/CAOGI/ACO
por: Oliver Goetze, Thorsten, et al.
Publicado: (2018)

The evaluation of surrogate endpoints
por: Burzykowski, Tomasz, et al.
Publicado: (2005)

Surrogate Endpoints in Medicine
por: Srivastava, Sudhir, et al.
Publicado: (2002)

Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma – the phase III “PREVENT”- (FLOT9) trial of the AIO /CAOGI /ACO
por: Götze, Thorsten O., et al.
Publicado: (2021)

The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI
por: Al-Batran, Salah-Eddin, et al.
Publicado: (2017)

Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) – a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)– the AIO/ CALGP/ ACO- GAIN-trial –
por: Goetze, Thorsten O., et al.
Publicado: (2020)

Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO)
por: Brunner, Thomas B, et al.
Publicado: (2007)

Prognostic Impact of Caspase-8, CDK9 and Phospho-CDK9 (Thr 186) Expression in Patients with Uterine Cervical Cancer Treated with Definitive Chemoradiation and Brachytherapy
por: Fleischmann, Maximilian, et al.
Publicado: (2022)

The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project
por: Sargent, Daniel J., et al.
Publicado: (2017)

Image-guided high-dose-rate brachytherapy for rectal cancer: technical note and first clinical experience on an organ-preserving approach
por: Fleischmann, Maximilian, et al.
Publicado: (2022)

Aios in coronatijd
por: Maria Greijn, Claudia, et al.
Publicado: (2020)

Treatment of peritoneal metastases from colorectal cancer
por: März, Loreen, et al.
Publicado: (2015)

Cytoreductive Surgery for Peritoneal Carcinomatosis from Gastric Cancer: Technical Details
por: Boerner, Thomas, et al.
Publicado: (2021)

Overview of Biomarkers and Surrogate Endpoints in Drug Development
por: Wagner, John A.
Publicado: (2002)

Is critical care ready for an economic surrogate endpoint?
por: Wilcox, M Elizabeth, et al.
Publicado: (2015)

Surrogate endpoints in early prostate cancer research
por: Williams, Scott
Publicado: (2018)

Surrogate endpoints… Uncommon for a common man!
por: Kumar, Ashish
Publicado: (2019)

Surrogate Endpoints for Late Kidney Transplantation Failure
por: Naesens, Maarten, et al.
Publicado: (2022)

Definitive, Preoperative, and Palliative Radiation Therapy of Esophageal Cancer
por: Fokas, Emmanouil, et al.
Publicado: (2015)

Präoperative Therapie des Rektumkarzinoms – Kritische Anmerkungen zur amerikanischen PROSPECT-Studie
por: Fokas, Emmanouil, et al.
Publicado: (2023)

Need for better reporting of trials with surrogate endpoints: SPIRIT|CONSORT-SURROGATE extensions
por: Ciani, Oriana, et al.
Publicado: (2022)

Statistical evaluation of surrogate endpoints: a systematic review
por: Ensor, Hannah, et al.
Publicado: (2013)

Bivariate network meta‐analysis for surrogate endpoint evaluation
por: Bujkiewicz, Sylwia, et al.
Publicado: (2019)

Biomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma
por: Medeiros, Felipe A.
Publicado: (2017)

Surrogate endpoints in trials: a call for better reporting
por: Ciani, Oriana, et al.
Publicado: (2022)

Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

Major QTLs, qARO1 and qARO9, Additively Regulate Adaxial Leaf Rolling in Rice
por: Jang, Su, et al.
Publicado: (2021)

AIOS proceedings: A response
por: Rajendran, Babu
Publicado: (2009)

19. AIO-Herbstkongress 2022
Publicado: (2023)

Complete response after chemoradiotherapy for rectal cancer: what is the reasonable approach?
por: Rödel, Claus, et al.
Publicado: (2017)

Kein Vorteil für die lokale Kontrolle nach Dosiseskalation der Strahlentherapie bei Patienten mit Ösophaguskarzinom nach einer definitiven Radiochemotherapie: randomisierte Phase-III-Studie ARTDECO
por: Fokas, Emmanouil, et al.
Publicado: (2022)

Geriatric assessment and the variance of treatment recommendations in geriatric patients with gastrointestinal cancer—a study in AIO oncologists
por: Büttelmann, M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2l9hbfpgnvq5jbevcgecgqruoe